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Summary: We evaluated a colorimetric method for the assay of uric acid in serum or urine, which utilises a
Trinder chromogenic System modified by the inclusion of 2,4,6-tribromo-3-hydroxybenzoic acid for oxidative
coupling to /^aminophenazone. Colour development (Amax: 512 nm) is complete within five minutes. Meas-
urement of a sample blank is not needed. The procedure involves pre-incubation with ascorbic acid oxidase
and detergent to eliminate interference by ascorbic acid and to abolish turbidity due to lipaemia; this
pretreatment was effective up to l .14 mmol/1 ascorbate and up to at least 25 mmol/1 triacylglycerol. Interference
by icteric sera was insignificant up to about 170 μιηοΐ/ΐ bilirubin. The method is linear up to at least 1428
μπιοΙ/1. In human serum and urine the procedure correlates well with HPLC and the uricase/?-aminophenazone
method on the SMAC analyser. Within-run and between-run imprecisions of the enzymic test were higher
than for HPLC, but did not exceed 1.2% (CV) and 2.5% (CV), respectively.
Attempts to improve the detection of H2O2 led to the
The concentration of uric acid in serum is the m st use of substituted phenols like 3,5-dichloro-2-hy-
important parameter for the diagnosis of gout. Of the droxybenzenesulphonic acid (5) and 2,4-dichloro-
methods developed (1^-4) for the determination of phenol (6). By oxidative coupling with /?-aminophen-
this analytej those utilizing the highly specific uricase1) azone, these compounds give a quinoneimine dye,
reaction, with subsequent estimation of the H2O2 from whose molar absorbance is 3 times greater than that
the oxidation of uric acid, have gained widespread of the original Trinder reaction (7).
The phenolic component in our uric acid /?-amino-
phenazone reagent is 2,4,6-tribromo-3-hydroxyben-
zoic acid (fig, 1). The molar absorbance of its coupling
1) Enzymes: product with D-aminophenazone exceeds that of the
Ascorbic acid oxidase (EC 1.10.3.3) j j u r , · + ι / ο Α n* ^^APeroxidase (EC 11117) compounds used by Fossati et al. (5) and Klose and
Uricase (EC 1.7.3.3) co-workers (6).
J. Clin. Chem. Clin. Biochem. / Vol. 27,1989 / No. 3
152 Dubois et al.: Enzymic and HPLC assays for uric acid comparcd
The present communication reporls the imprecision,
analytical ränge limits, interference by endogeneous
serum constituents and accuracy of the uric acid p-
aminophenazone test, and compares them with those
of an HPLC method of established accuracy.
Materials and Methode
Analytical procedures
The Boehringer Mannheim uric acid /?-aminophenazone test kit
for mechanized analyses in serum, plasma and urine (Cat. No.
908 240, Boehringer Mannheim GmbH, FRG) was the subject
of this evaluation study. Reagent l contains 0.1 mol/1 potassium
phosphate (pH 7.8); 6 g/l poly(ethyleneglycol-alkylether); 9.6
mmol/1 sodium cholate; 24 mmol/1 2,4,6-tribromo-3-hydroxy-
benzoic acid; > 5 kU/1 ascorbate oxidase1).
The reaction is started by addition of reagent 2 [0.1 mol/1
potassium phosphate, pH 7.8; 60 mmol/1 potassium hexacy-
anoferrate (II); 0.12 mmol/1 4-aminoantipyrine; > l kU/1
peroxidase1); > 0.5 kU/1 uricase1)]. The reaction sequence is
depicted in figure 1.
The test was run on a Boehringer Mannheim/Hitachi 705 anal-
ysis System with Instrument settings according to the manufac-
turer's recommendations:
Sample:
Temperature:
Sample volume:
Volume of Rl:
Volume of R2:
Measuring wavelength:
Reference wavelength:
Preincubation time:
Incubation time:
serum, urine (urine: diluted l: 5
with redistilled water)
25 °C
10
350
70
600 nm
505 nm
5 min
5 min
For comparison purposes, the Boehringer Mannheim uricase
/7-aminophenazone test (Cat. No. 157104, Boehringer Mann-
heim GmbH, FRG) was used on a SMAC analyser äs described
by Klose et ai. (6).
HPLC was a reverse phase procedure developed by Greiling et
al. (8).
GC/MS measurements of uric acid concentrations were per-
formed äs published by Siekmann (9) in four human serum-
based lyophilized sera.
All mechanized analyses with the uric acid /7-aminophenazone
reagent were calibrated with the "calibrator for automated
Systems" (Cat. No. 759 350, Lot No. 151264, Boehringer Mann-
heim GmbH, FRG) which is based on lyophilized human
serum. The calibration factor was determined by HPLC (10).
For purposes of quality control, we used four control sera
(Precinorm® U, Cat. No. 171735, Lot No. 152620 and Lot
No. 1-502; Precipath® U, Cat. No. 171 760, Lot Nos. 151 608
and 1-528, Boehringer Mannheim Gmbü, FRG), an aqueous
Standard solution (Preciset® Uric Acid, Cat. No. 125 628, Boeh-
ringer Mannheim GmbH, FRG) and human serum-based ly-
ophilized Standards.
In order to prevent degradation of uric acid via urate anion
free radical formation (11), the samples were stored in the dark
until analysis.
Imprecision
Pool sera and control sera were analyzed with the uric acid p-
aminophenazone test and the reference method at four different
coöcentration levels. Within-series imprecision was derived
from 20 measurements at each concentratiön level with fresh
sera. Between-day imprecision was determined from measure-
ments over 20 days with deep-frozen human sera and cöntrol
sera.
Linearity and analytical ränge limits
A dilution series, prepared by mixing varying amounts of a
uric acid-supplemented human serum and the same serum with-
out added uric acid, was used to check the linearity. The lower
limit of detection was calculated according to Kaiser (12), i.e.
from the mean plus three S. D. of 20 measurements of the
blank.
Accuracy
The accuracy of the new method was investigated äs follows.
(A) Seventy fresh human sera and 40 urine samples covering
a wide concentration ränge were assayed with the new uric
acid /^aminophenazone test on the Hitachi 705, with the
uricase p-aminophenazone methpd on the SMAC änalyser,
and with the HPLC method, and the results were coni-
pared.
(B) Four human serum-based lyophilized Standards were ana-
lysed with the new method, with the reference method (GC/
MS) and with the HPLC method, and the results were
compared.
UricQse ™ VV0
O^N^N:H H
Allantoin
C0 2 +H 2 0 2
Br COOH H2N CH3 Br COOH
+ ·*· 2H20
Br
2,4,6-Tribromo-
3-hydroxybenzoic ocid , . . . . .4-Ammoantipynne
(p-Aminophenazone, PAP) Quinohe dye
E5ionm?2900m -mol
Fig. 1. Reaction principle of the enzymic uric acid /7-aminophenazone (PAP) method.
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(C) Using the new method, uric acid was measured in duplicate
in a 384 μιηοΐ/l aqueous primary Standard solution (SRM
No. 913, National Bureau of Standards) which was used
for standardization of the HPLC reference method.
(D) Using the new method, uric acid was measured in duplicate
in a human serum-based reference material (SRM No. 909,
National Bureau of Standards) with a certified value for
uric acid which was also confirmed· by the HPLC method
used in the present study.
(E) The recovery of test-specific target values was measured in
duplicate in control sera over a period of 20 days, using
the new method. The test-specific target values were estab-
lished with a reference standardization in three independent
laboratories using HPLC (8). The data obtained by each
laboratory for each of the respective sera in five independ-
ent runs and duplicate measurements were used for the
assignment of target values.
Interference
Interference by haemoglobin was evaluated by adding increas-
ing amounts of erythrocyte lysates to aliquots of pooled serum.
The haemoglobin concentrations were quantified with a cyan-
methaemoglobin method (Cat. No. 124729, Boehringer Mann-
heim GmbH, FRG).
We used two methods to examine the effect of bilirubin on the
uric acid /?-aminophenazone reagent: the new method was ap-
plied to a series of specimens with added crystalline bilirubin,
and to icteric sera containing up to 461 μηιοΐ/ΐ native bilirubin;
the same samples were also analysed with the HPLC method.
Bilirubin concentrations were measured with the DPD method
(Cat. No. 398128, Boehringer Mannheim GmbH, FRG).
Possible interference by lipaemia was simulated by supple-
menting serum with Intralipid® (Pfrimmer & Co., FRG). A
series of concentrations was prepared by mixing an aliquot of
serum containing 10 g/l Intralipid® with an aliquot of the same
Intralipid®-free serum. To compensate for the variable dilution
resulting from the addition of lipids, we added proportional
amounts of 0.154 mol/1 NaCl solution.
A total of 34 pharmaceuticals (see tab. 1) was tested in vitro
according to I.e. (13).
Potential interference by ascorbic acid was investigated with a
series of concentrations prepared by mixing aliquots of an
ascorbic acid-supplemented serum pool (5.68 mmol/1) with var-
iable amounts of the same serum without ascorbic acid. For
these studies we used deep-frozen human sera.
Statistics
Regression was analysed s described by Passing & Bablok (14).
Results
Imprecision
The CV values obtained with the uric acid /?-amino-
phenazone test did not exceed 1.2% and 2.5% for
within-run and between-run imprecisipn, respectively
(tab. 2). The imprecision study conducted with HPLC
s the reference method revealed a within-run varia-
bility of about 0.5% CV and between-run imprecision
CVs in the r nge of 0.5% to 0.8% (tab. 3).
Tab. 1. Pharmaceuticals tested for possible interferences in vi-
tro
Substances Maximum "Therapeutic
concentration concentration'1
tested
[mg/1] [mg/1]
Acetylsalicylic acid
Allopurinol
Ampicillin
Ascorbic acid
Bezafibrate
Calcium dobesilate
Carbochromen
Chloramphenicol
Chlordiazepoxide
Furosemide
Glibenclamide
Indometacine
Methaqualone
oc-Methyldopa
Nicotinic acid
Nitrofurantoin
Noramidopyrine
Oxazepam
Oxyphenbutazone
Oxypurinol
Oxytetracycline
Paracetamol
Phenobarbitone
Phenprocumon
Phenazopyridine
Phenytoin
Probenecid
Procaine
Pyridamol
Pyritinol
Quinidine
Sulphamethoxazole
Theophylline
Trimethoprim
1000
300
1000
1000
100
200
30
200
30
1750
1
100
50
100
400
18
200
10
240
300
160
200
250
20
25
200
1000
2
100
20
60
600
200
18
200
30
200
30
10
100
3
20
3
10
0.1
20
5
6
40
6
20
2
20
30
16
20
50
2
2.5
20
200
2
30
2
6
80
20
2
Tab. 2. Imprecision of the enzymic uric acid /7-aminophenazone
method
Imprecision
Within run (n = 20)
Between run (n = 20)
Mean
Qimol/1]
263
317
499
554
222
' 263
339
549
CV
[%]
0.8
1.2
1.0
0.4
2.0
2.5
2.5
2.0
Tab. 3. Imprecision of uric acid determinations with HPLC
Imprecision
Within run (n = 20)
Between run (n = 20)
Mean
[μηιοΐ/ΐ]
266
322
513
552
245
357
511
592
CV
[%1
0.5
0.5
0.5
0.4
0.7
0.8
0.5
0.8
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Analyt ica l r nge l imits , l ineari ty
The lower detection limit of the enzymic uric acid
test, determined according to Kaiser (12), was found
to be practically zero. This value was confirmed by
measuring the dose-response relationship in a series
of aqueous Solutions at uric acid concentrations of
zero to 60 μηιοΐ/ΐ (data not shown).
The dynamic r nge of linearity of the enzymic test
was assessed by using human serum containing vary-
ing amounts of added uric acid. Within the tested
concentration r nge, which extended up to 1428
μπιοΐ/ΐ, the method was found to be linear (fig. 2).
Interferences
The usual anticoagulant concentrations (100 g/l NaF,
10 g/l EDTA, 100 · 103 U/l heparin, 50 g/l citrate) do
not influence the test results with the enzymic reagent.
Turbidity caused by lipaemia did not interfere in the
enzymic uric acid test, s demonstrated by the failure
of 10 g/l added Intralipid® to produce aberrant values.
Up to 186 μπιοΐ/ΐ haemoglobin, haemolysis causes no
noticeable interference in the new enzymic test.
Studies on interference by bilirubin were equivocal.
Addition of commercial bilirubin to human serum led
to a proportional decrease in the apparent uric acid
concentration. When 427 μιηοΐ/ΐ crystalline bilirubin
was added to serum containing uric acid in the normal
r nge, the resulting decrease in the apparent uric acid
concentration was approximately 60%.
When we compared the uric acid recovery of the
enzymic method with that of HPLC in native icteric
sera, we also invariably observed decreased apparent
uric acid concentrations. In this case, however de-
crease was markedly smaller and, furthermore, it de-
pended on the particular serum sample. For example,
with an icteric specimen containing 461 μιηοΐ/l bili-
rubin we found a 22% deviation from the Value ob-
tained with HPLC; on the other hand, other serum
specimens with 137 — 171 μιηοΐ/ΐ bilirubin, showed no
significant interference.
Of the 34 drugs tested, only calcium d besilate, o>
methyldopa and noramidopyrine interfered with the
present uric acid /^aminophenazone test at therapeu^
tic concentrations. Calcium d besilate at 100 mg/1, a-
methyldopa at 100 mg/1 and noramidopyrine at 20
mg/1 caused apparent decreases in the uric acid con-
centration of about 50, 10 and 11%, respectively.
Ascorbic acid does not cause errone usly low results,
until its concentration exceeds 1.14 mmol/1.
Accur cy
As shown in figure 3, recovery from c ntrol sera with
the /7-aminophenazone reagent is 4—10% lower than
with GC/MS and HPLC.
The recovery of test-specific target values with the
new test in four different c ntrol sera was found to
vary from 99.5 to 102.6% (tab. 4).
110
105
^100
95
90
500 1000 1500 2000
Uric acid, target value ίμπηοΐ/ΐ]
80
C ntrol serum 1
GC/MS: 228.4 μπιοΐ/ΐ
C ntrol serum 2
GC/MS: 334.3 μπηοΐ/ΐ
Cpntrol serum 3
GC/MS: 416.4 μπηοΐ/ΐ
C ntrol serum 4
GC/MS: 466.4 μΓηοΙ/Ι
Recovery [%J
90 100
J92.8
97.9
89.7
99.8
96.3
J95.3
99.4
99.9
Fig. 2. Linearity of the enzymic uric acid /7-aminophenazone Fig. 3. Recovery of GC/MS values in c ntrol sera.
(PAP) method.
 aWhite columns: Uric acid PAP; gray columns: HPLC
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Tab. 4. Recovery of test-specific target values in control sera
with the uric acid p-aminophenazone test
Target value
[μπιοΐ/ΐ]
246.3
264.7
536.6
558.0
Recovery ±
[%]
102.6 ± 3.1
102.2 ± 2.8
101.4 ± 1.6
99.5 ± 3.7
S.D.
Additionally, we examined the recovery with this col-
our test in the aqueous primary Standard used for
HPLC calibration and a human serum-based refer-
ence material. These measurements resulted in
100.3% and 99.9% recoveries of the respective target
values (aqueous primary Standard: 384 μηιοΐ/ΐ; human
serum-based control material: 483 μιηοΐ/ΐ).
For method comparison, we analysed human serum
and urine samples with the proposed method and
HPLC. Furthermore, the uric acid /j-amin phenazone
test was compared with the uricase/7-aminophenazone
method on the SMAC analyser in human sera. We
found the present test (y) to agree well with HPLC
(x) in both human serum (y = 0.30 + 0.97x;
r = 0.995) and urine (y = 2.00 + 1.03x; r = 0.989)
(fig. 4, 5). A similar good agreement exists between
the proposed method (y) and the uricase /j-amino-
phenazone test (x) on the SMAC analyser
(y =5 - 0.05 + l.OOx; r = 0.981, flg. 6).
1000
800
E
600
ε
DL
400
200
200 400 600 800
Urie acid (HPLC method) ΓμιϋοΙ/ΊJ
1000
Fig. 4. Comparison of the uric acid p-aminophenazone (PAP)
test (y) with HPLC (x), using human sera (n = 70,
y = 0.30 + 0.97x, r « 0,995).
8000
2000 4000 6000
Uric acid (HPLC method) Γμπηοΐ/ϋ
8000
Fig. 5. Comparison of the uric acid /7-aminophenazone (PAP)
test (y) with HPLC (x), using urine samples (n = 40,
y = - 2.00 + 1.03x, r = 0.989).
800
•o 600
E .
400
Z) 200
y = x
200 400 600
Uric acid (uricase PAP method) Εμπηοΐ/ l )
800
Fig. 6. Comparison of the uric acid p-aminophenazone (PAP)
test (y) with the uricase p-aminophenazone (PAP)
method on the SMAC analyser (x), using human sera
(n = 70, y = - 4.54 H- l.Olx, r = 0.990).
Discussion
We evaluated an enzymic reagent for the determina-
tion of uric acid in serum and urine which utilizes a
modified Trinder chromogenic system. The phenolic
compound used couples oxidatively with /?-amino-
phenazone, forming a quinone imine dye with im-
proved molar absorbance. Hence, the sample/reagent
ratio in our assay could be kept low, thus reducing
possible interference by sample constituents to a min-
imuin, while retaining satisfactory sensitivity and pre-
cision.
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Optimization of component concentrations and assay
pH ensured completion of colour development within
5 min at 25 °C or 37 °C, and a dynamic measuring
r nge extending from zero concentration up to a level
probably exceeding the highest level tested in this
study which was 1428 μιηοΐ/ΐ. Because of the short
incubation times required for preincubation and max-
imum colour development, this assay can be conve-
niently adapted to mechanised Systems which are ca-
pable of pipetting a Start reagent.
In order to overcome the well known interference of
ascorbic acid in Trinder chromogenic Systems, a prein-
cubation step has been included in this new assay
during which any ascorbic acid is destroyed by as-
corbate oxidase. The ascorbate degrading capacity in
our assay is sufficient to eliminate ascorbate concen-
trations greater than l mmol/1 within 5 min,
Interference by the turbidity of lipaemic sera was
avoided in our test by addition of detergent to the
preincubation solution, which proved to be effective
at least up to ^concentration of 10 g/l added lipid,
being equivalent to about 28.6 mmol/1 triacylglycerols
(15).
Interference by bilirubin due to chemical and simple
spectral effects has been reported for several peroxi-
dase-coupled enzymic colour tests (16). When we
measured uric acid concentrations with the new en-
zymic /7-aminophenazone reagent in native icteric
sera, however, we consistently observed significantly
decreased recoveries of HPLC-defined analyte con-
centrations only when the bilirubin concentration was
above 170 μτηοΐ/ΐ. An explanation of this finding may
be that the different bilirubin species contained in the
individual pathological sera (17) have a different ca-
pacity for interference with the assay. Support of this
view comes from data obtained recently with an en-
zymic creatinine /?-aminophenazone method (18). In
these studies, Guder et al. found variable relationship
between assay interference and the bilirubin content
of icteric sera, and significant disturbance was not
detected up to 120 μιηοΐ/ΐ bilirubin.
In the analysis of human serum and urine samples,
s well s aqueous primary Standard solution and
human serum-based reference material with the en-
zymic /7-aminophenazone method, we obtained results
agreeing closely with those attained with HPLC,
which has been proposed s reference method for uric
acid determination (19). In control sera, on the other
hand, the enzymic test yielded somewhat lower values
compared with HPLC. Therefore, it will be essential
to define specific target val es in c ntf l material for
the /7-aminophenazone method.
In conclusion, the enzymic pirocedure evaluated in
this study is considered to be a reliable method for
routine uric acid determinations. Only samples with
uncommonly high bilirubin levels, and specimens
from patients receiving calcium dobesilate, a-meth-
yldopa and noramidopyrine may give poof assay re^
sults by the proposed method. In such cases analyses
should be run with a method known to be insensitive
to these interferences.
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